STOCKHOLM, Sweden--(BUSINESS WIRE)--The EQT V fund (“EQT”) is pleased to announce that it has entered into an agreement to acquire Dako Denmark A/S (“Dako” or “Dako Group”), one of the world’s leading cancer diagnostics companies with headquarters in Glostrup, Denmark, for an enterprise value of DKK 7,250m. Dako’s current main shareholders include descendants of the company’s founder Niels Harboe (61%), Novo Nordisk A/S (27%) and others (12%).
